

INFORME DE BÚSQUEDA DE PATENTES				
N° de solicitud: 16050106				
CRITERIOS PARA LA BÚSQUEDA (Anexar pantallazo o reporte en PDF, junto con los boléanos utilizados*. Para el caso de secuencias, anexar alineamientos)				
Palabras clave utilizadas		Antibodies or antibody anti-FGFR2, BEK fibroblast growth factor receptor, receptor protein tyrosine, fucose removal, ADCC, treating or diagnosing cancer.		
CLASIFICACIONES UTILIZADAS PARA LA BÚSQUEDA		CIP: C07K 16/28, A61K 39/00, A61P 35/00.		
		CPC (Opcional): -		
DOCUMENTOS CONSIDERADOS RELEVANTES (documentos patentes, literatura no patente, etc...)				
Informes/Base de datos	N° de solicitud/ Autor**	Fecha de Publicación/Presentación (DD/MM/AAAA)	Reiv. afectadas (Con indicación, si procede, de las partes relevantes o números de secuencias)	Categorías especiales de los documentos citados***
SIPI	CO14234940	23/10/2014	-	-
EPO (11/11/2014)	WO2010054265	14/05/2010	-	Y
	Yamane-Ohnuki N. <i>et al.</i> , 2009.	01/05/2009	Rv. 1 a 20 (Pág. 232, Col. 1 - Pág. 234, Col. 2).	Y
	Niwa R. <i>et al.</i> , 2005.	30/11/2005	Rv. 1 a 20 (Pág. 152, Fig. 1 - Pág. 159, Col. 1).	Y
Patbase*	WO2010111367	30/09/2010	-	A
	US20100196364	05/08/2010	Rv. 1 a 20 (Pág. 5, Párr. 42 y 43 – Fig. 13A y B).	Y
	US6323316	27/01/2001	-	A
	US20110305687	15/12/2011	-	A
	US20110135657	09/06/2011	-	A
	US20050147612	07/07/2005	-	A
	WO2002031140	18/04/2002	-	A
Patent Lens	US20100196364	05/08/2010	La SEQ ID NO: 5 presenta 100% de identidad y cobertura respecto a la SEQ ID NO: 4 reclamada en la solicitud.	X
	US20100196364	05/08/2010	La SEQ ID NO: 2 presenta 100% de identidad y cobertura respecto a la SEQ ID NO: 5 reclamada en la solicitud.	X
*** Categorías especiales de documentos citados:				
“A” documento que define el estado general de la técnica no considerado como particularmente relevante. “E” solicitud de patente o patente anterior pero publicada en la fecha de presentación internacional o en fecha posterior. “P” documento publicado antes de la fecha de presentación internacional pero con posterioridad a la fecha de prioridad reivindicada.		“X” documento particularmente relevante; la invención reivindicada no puede considerarse nueva o que implique una actividad inventiva por referencia al documento aisladamente considerado. “Y” documento particularmente relevante; la invención reivindicada no puede considerarse que implique una actividad inventiva cuando el documento se asocia a otro u otros documentos de la misma naturaleza, cuya combinación resulta evidente para un experto en la materia.		
**** Indicar entre paréntesis la Autoridad que realizó la búsqueda o el informe preliminar Ejs: EPO, JP, INAPI.				

	- Yamane-Ohnuki N. <i>et al.</i> , 2009. Production of therapeutic antibodies with controlled fucosylation. mAbs, 20090501 Landes Bioscience, US. Vol: 1, Nr: 3, Page(s): 230 – 236. - Niwa R. <i>et al.</i> , 2005. IgG subclass-independent improvement of
--	---

Literatura no patente

antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. JOURNAL OF IMMUNOLOGICAL METHODS, 20051130 ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL. Vol: 306, Nr: 1-2, Page(s): 151 – 160.

- Lee, M. *et al.*, 2011. Acidic Fibroblast Growth Factor (FGF) Potentiates Glial-mediated Neurotoxicity by Activating FGFR2 IIIb Protein.
- Liu, ZY *et al.*, 2011. Fibroblast Growth Factor Receptor Mediates Fibroblast-Dependent Growth in EMMPRIN-Depleted Head and Neck Cancer Tumor Cells.
- Asaoka, Y. *et al.*, 2011. New targeted therapies for gastric cancer.
- Bai, A. *et al.*, 2010. Essential role of fibroblast growth factor receptor 2 (FGFR2) in tumorigenesis of human cancers harboring FGFR2 amplification demonstrated by a functional blocking antibody.

Fecha del reporte de búsqueda:

10/08/2017

Búsqueda en PatBase

104) Family number: 49952746 (US2011305687A)

Similar • Translate • Full-text • Status • Citations

Title: [EN] ANTI-FGFR2 ANTIBODIES

Abstract: Source: US2011305687A [EN] Monoclonal antibodies that bind and inhibit biological activities of human FGFR2 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation or overexpression of FGFR2

Classifications: Classification Explorer

International (IPC 8-9): A61K A61K39/00 A61K39/395 A61P35/00 C07K16/00 C07K16/18 C07K16/28 C07K16/46 C12N15/09 C12N15/13 C12P21/02 C12P21/08 (Advanced/Invention)


CPC: C07K16/2863 A61K2039/505 C07K2317/24 C07K2317/73 C07K2317/76 C07K2317/92

European: C07K16/28G K61K39/505 M07K317/240 M07K317/730 M07K317/760 M07K317/920

US: 424/133.1 424/133.100P 424/158.1 424/158.100S 435/252.33 435/252.330S 435/320.1 435/320.100S 435/328 435/328S 435/334 435/334S 435/375 435/375S 435/69.6 435/69.600S 530/350 530/387.1 530/387.3 530/387.300S 530/387.7 530/388.22 530/389.1 530/389.100S 536/23.53 536/23.530S

Family: Family Explorer

Publication number	Publication date	Application number	Application date	Links
AU2011253101 AA	20111117	AU20110253101	20110511	
AU2011253101 AB	20130502	AU20110253101	20110511	
CA2800311 AA	20121109	CA20112800311	20110511	
CN102905723 A	20130130	CN201180023241	20110511	
EP2569012 A2	20130320	EP20110781211	20110511	



89) Family number: 44990486 (US2010196364A)

Similar • Translate • Full-text • Status • Citations

Title: [EN] MONOCLONAL ANTIBODIES TO FIBROBLAST GROWTH FACTOR RECEPTOR 2

Abstract: Source: US2010196364A [EN] The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.

Classifications: Classification Explorer

International (IPC 8-9): A61K38/00 A61K39/00 A61K39/395 A61P1/04 A61P35/00 C07K16/00 C07K16/28 C07K16/32 C07K16/46 C12N15/02 C12P21/08 (Advanced/Invention);

A61K39/395 A61P35/00 C07K14/71 C12P21/08 (Advanced/Non-invention);

A61K39/395 A61P35/00 C07K16/18 C12P21/08 (Core/Invention);

A61K A61P C07K C12P (Subclass/Invention)

International (IPC 1-7): A61K39/395


CPC: C07K16/2863 A61K2039/505 C07K2317/24 C07K2317/33 C07K2317/92

European: C07K16/28G K61K39/505 M07K317/240 M07K317/330 M07K317/920

US: 424/133.1 424/133.100P 424/133.100S 424/135.1 424/135.100P 424/141.1 424/142.1 424/142.100S 424/143.1 424/143.100S 435/320.1 514/19.3 530/387.3 530/387.300S 530/388.1 530/388.15 530/388.22 530/388.220S 536/23.53

Family: Family Explorer

Publication number	Publication date	Application number	Application date	Links
AU2009313357 AA	20100514	AU20090313357	20091106	
AU2009313357 BB	20150611	AU20090313357	20091106	
BRPI0917315 A2	20151117	BR2009PI17315	20091106	
CA2733668 AA	20100514	CA20092733668	20091106	



Title: [EN] **ANTIBODIES** BLOCKING FIBROBLAST GROWTH FACTOR RECEPTOR ACTIVATION AND METHODS OF USE THEREOF

Abstract: Source: US2010047251A [EN] The present invention is related to **antibodies** with binding affinity to fibroblast growth factor receptor 2 (**FGFR2**) optionally with binding affinity to other FGF receptors, which block both ligand-dependent and constitutive ligand independent receptor activation. Specifically, the present invention relates to **antibodies** with high affinity to more than one FGF receptor subtype, and fragments thereof, useful in treating disorders including cell proliferative diseases.

Classifications: [Classification Explorer](#)


International (IPC 8-9): A61K39/00 A61K39/39 A61K39/395 A61P35/00 C07K16/00 C07K16/18 C07K16/22 C07K16/28 C12P21/08 (Advanced/Invention); C07K14/71 (Advanced/Non-invention);

A61K39/00 A61K39/39 A61K39/395 A61P35/00 C07K16/00 C07K16/18 C12P21/08 (Core/Invention)
CPC: C07K2317/73 C07K2317/76 C07K16/2863 C07K2317/21 C07K2317/55 C07K2317/622

European: C07K16/28G M07K316/960 M07K317/210 M07K317/550 M07K317/622

US: 424/130.1 424/130.100S 424/133.1 424/135.1 424/145.1 424/145.100P 424/178.1 424/178.100S 530/387.1 530/387.100S 530/387.3 530/388.1 530/388.100S 530/391.1 530/391.100S

Family: [Family Explorer](#)



Búsqueda en Thomson Innovation

THOMSON INNOVATION® Welcome Ruth

PATENT SEARCH PUBLICATION NUMBER

FIELD EXPERT Change collections: [US Grant](#), [US App](#), [EP Grant](#), [EP App](#), [WO App](#)

Title/Abstract/Claims: ((antibodies OR antibody) AND FGFR2) AND
IPC-Any: C12N 15/09

Preview/edit query: CTD-(((antibodies OR antibody) AND FGFR2)) AND IC-((C12N001509))

Search Results: 26 record(s) found out of 23,557,901 searched (display limit 60,000) 0 record(s) selected

Item	Publication Number	Assignee/Applicant	Publication Date	Current IPC

Thomson Innovation Record View

www.thomsoninnovation.com/tip-innovation/recordView.do?pager.offset=16&recordCount=1&parentIds=0&totalRecords=38&totalFamilyRec=38...

Literature Record View - Fibroblast Growth Factor Receptor Mediat...

Record View: Literature

Add to Work File | Mark Record | Download | Watch Record | Translate | Citation Map | Highlight | Print

Jump to: Biblio Abstract Index Citation Information Other Document Information

Biblio

Title ?
Fibroblast Growth Factor Receptor Mediates Fibroblast-Dependent Growth in EMMPRIN-Depleted Head and Neck Cancer Tumor Cells

Author(s) ?
[Liu, ZY](#) (Liu, Zhiyong); [Hartman, YE](#) (Hartman, Yolanda E.); [Warram, JM](#) (Warram, Jason M.); [Knowles, JA](#) (Knowles, Joseph A.); [Sweeny, L](#) (Sweeny, Larissa); [Zhou, T](#) (Zhou, Tong); [Rosenthal, EL](#) (Rosenthal, Eben L.)

Source ?
[MOLECULAR CANCER RESEARCH](#) Volume: 9 Issue: 8 Article Number: - DOI: 10.1158/1541-7786.MCR-11-0043 Published: AUG 2011 Page: 1008-1017

Organization ?
Univ Alabama; University of Alabama Birmingham; University of Alabama System; Dept Surg; Div Otolaryngol Head & Neck Surg; Univ Alabama; University of Alabama Birmingham; University of Alabama System; Dept Pathol; Div Immunol Rheumatol; Univ Alabama; University of Alabama Birmingham; University of Alabama System; Dept Med; Div Immunol Rheumatol

Organization Address ?
Univ Alabama, Dept Surg, Div Otolaryngol Head & Neck Surg, Birmingham, AL 35294 USA ([Liu, Zhiyong](#) [Hartman, Yolanda E.](#) [Knowles, Joseph A.](#) [Sweeny, Larissa](#) [Rosenthal, Eben L.](#))
Univ Alabama, Dept Pathol, Div Immunol Rheumatol, Birmingham, AL 35294 USA ([Warram, Jason](#)

Highlighting

By Term By Field

antibody (1)
Abstract

FGFR2 (6)
Abstract

antibody FGFR2

Record View: Literature

? Help

Add to Work File | Mark Record | Download ▼ | Watch Record | Translate ▼ | Citation Map | Highlight | Print

 Jump to: Biblio Abstract Index Citation Information Other Document Information

Biblio

Title ?

Essential role of fibroblast growth factor receptor 2 (**FGFR2**) in tumorigenesis of human cancers harboring **FGFR2** amplification demonstrated by a functional blocking **antibody**

Author(s) ?

[Bai, A](#) (Bai, A.); [Meetze, K](#) (Meetze, K.); [Vo, N](#) (Vo, N.); [Kollipara, S](#) (Kollipara, S.); [Mazsa, E](#) (Mazsa, E.); [Winston, W](#) (Winston, W.); [Weiler, S](#) (Weiler, S.); [Lerner, L](#) (Lerner, L.); [Gyuris, J](#) (Gyuris, J.); [Weng, Z](#) (Weng, Z.)

Source ?

[EJC SUPPLEMENTS](#) Volume: 8 Issue: 7 Article Number: - DOI: 10.1016/S1359-6349(10)71935-2 Published: NOV 2010 Page: 75-75

Organization ?

AVEO Pharmaceut; Drug Discovery; AVEO Pharmaceut; Translat Res

Organization Address ?

AVEO Pharmaceut, Drug Discovery, Cambridge, MA USA ([Bai, A](#), [Meetze, K](#), [Vo, N](#), [Kollipara, S](#), [Mazsa, E](#), [Winston, W](#), [Weiler, S](#), [Gyuris, J](#), [Weng, Z](#).)
AVEO Pharmaceut, Translat Res, Cambridge, MA USA ([Lerner, L](#).)

Publication Year ?

2010

Highlighting

☒ By Term ☐ By Field

antibody (1)

Title

FGFR2 (2)

Title

◀ antibody ▶
◀ FGFR2 ▶